Pfizer announced positive data of its COVID-19 shot regimen for children under 5 years; providers gear up for increased challenges in distributing abortion medication; hypoallergenic baby formula shipments arrive in the United States.
Pfizer has announced 3 doses of its vaccine, developed with BioNTech, offer strong protection for children younger than 5, The Associated Press reports. The company will provide the data to US regulators later this week as babies, toddlers, and preschoolers remain the only cohort without authorized vaccines against COVID-19. There are approximately 18 million children under the age of 5 years in the United States, while the FDA has already begun reviewing data from Moderna and its 2-dose regimen. The Pfizer doses are one-tenth of the amount adults receive and, according to a company press release, the 3-dose regimen enhanced children’s antibodies enough to meet emergency authorization criteria.
In the wake of the leaked Supreme Court draft opinion indicating justices were poised to overturn Roe v Wade—the decision that guaranteed a woman legal rights to an abortion—physicians, midwives and nurse practitioners are gearing up to deal with a potential surge in demand for abortion medications, NPR reports. The groups are also preparing to face obstacles as states with newly enacted abortion restrictions work to limit online access to the pills. The COVID-19 pandemic has ushered in an era where receiving a telehealth abortion is more convenient to patients. Data from the Guttmacher Institute show that as of February 2022, medication-induced abortions account for over half of all the procedures performed in the country.
As the country continues to struggle with mass baby formula shortages, the first shipment from overseas has arrived in the United States from Europe, ABC News reports. The plane carried enough specialty formula for more than half a million baby bottles while more shipments are expected to arrive soon. In February, the nation’s largest baby formula manufacturing plant temporarily closed due to contamination concerns and safety issues. The formulas are hypoallergenic, specifically made for children with cow’s milk protein allergy. The first shipment was delivered to Indianapolis, Indiana and contained about 15% of the specialty formula needed in the United States.
California Aims for Equity by Redefining Cancer Care
December 8th 2023Authors highlight key aspects of the California Cancer Care Equity Act, including its focus on Medi-Cal beneficiaries, the requirement for managed care plans to contract with specialized cancer centers, and the definition of complex cancers.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
What We’re Reading: RSV Vaccine Demand; Permanent Contraception; Drug Negotiation Impact
December 8th 2023The Biden administration recently met with manufacturers of respiratory syncytial virus (RSV) immunizations to encourage them to increase access to the vaccine; since the Dobbs v Jackson decision, many patients have been seeking more permanent reproductive health care solutions; a Mathematica analysis showed that Medicare prescription drug price negotiations could have cut seniors’ out-of-pocket costs by nearly a quarter had the program been in effect in 2021.
Read More
Insufficient Data, Disparities Plague Lung Cancer Risk Factor Documentation
September 24th 2023On this episode of Managed Care Cast, we speak with the senior author of a study published in the September 2023 issue of The American Journal of Managed Care® on the importance of adequate and effective lung cancer risk factor documentation to determine a patient's eligibility for screening.
Listen
New Insights on Breast Cancer Outcomes Among Sexual, Gender Minorities
December 7th 2023Despite there being a great demand for data collection on sexual orientation and gender identity in the cancer space, individuals who identify as a sexual and gender minority remain poorly represented.
Read More
Research Reveals the Role of Structural Racism in Lung Cancer Risk
December 7th 2023Spanning 22 studies, the analysis illuminated housing disparities, occupational hazards, unequal health care access, economic inequality, and discriminatory industry practices and how they collectively contribute to heightened lung cancer risks.
Read More